![Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37]](https://cedclinic.com/wp-content/uploads/2026/07/ced-pexels-5021600-150x150.jpg "Cbd Vs Hemp Gummies: Which Is Right For Your Wellness Routine? [Tz8JKLqMk37] 19")
Persistent and Debilitating Muscle Spasms | Utah Medical Cannabis Guidelines
Utah's spasticity clinical guidelines provide evidence-based protocols for medical cannabis use in persistent and debilitating muscle spasms. These guidelines help clinicians with dosing and delivery methods for spasticity management. Patients with…
Quantum Biopharma Seeks FDA Clearance for Lucid-MS Phase 2 Trial
Quantum Biopharma is advancing a cannabis-based therapeutic phase 2 trial for Lucid-MS. This trial targets cognitive symptoms in multiple sclerosis patients. The phase 2 trial is a critical step to evaluate efficacy beyond safety.
Gut Cells Prime T-Cells to Trigger Brain Inflammation in MS: Study Overview
This study highlights the gut-brain-immune axis connection as a key factor in multiple sclerosis pathology. Gut cells prime T-cells that trigger brain inflammation, revealing new therapeutic targets. Understanding this connection may improve personalized…
Over 70% of MS Patients in Rehab Take 5+ Medications, Study Finds
Polypharmacy in MS rehabilitation is a significant clinical challenge, with over 70% of patients taking five or more medications. This study highlights the potential for cannabis to consolidate therapies and reduce drug interactions. Understanding…
New Research Project Explores Menopause in Women with MS
Menopause multiple sclerosis research is uncovering how hormonal transitions affect disease progression and symptom management in women. This new study focuses on neuroinflammation and hormonal changes unique to women with MS during menopause.…
Honoring the Trailblazers with MS Who Changed Cannabis Policy
Multiple sclerosis cannabis advocacy has played a pivotal role in shaping medical cannabis policy. MS patients were among the first to demonstrate therapeutic benefits of cannabinoids in clinical settings. Their efforts helped establish evidence-based…
Survey of 47 Trials Maps Cannabinoid Research in Neurology—But Evidence Gaps Remain Large
This review maps cannabinoid clinical trials neurology, highlighting 47 completed studies focused on conditions such as Multiple Sclerosis and Fibromyalgia. It reveals significant evidence gaps due to non-standardized protocols and outcome measures. The…
MS Cases Double in England Over 20 Years; Life Expectancy Rises
Multiple sclerosis spasticity cannabis treatments are gaining attention as MS cases double in England over 20 years. Improved survival rates mean more patients live longer with chronic symptoms. Cannabis therapies offer promising options for managing…
Variations in p21 Protein May Explain Why Some MS Types Progress Faster
Emerging research on multiple sclerosis biomarkers highlights the role of p21 protein variations in disease progression. Understanding these biomarkers may help identify patients at higher risk for aggressive MS types. This insight supports the…
Mapping the Clinical Trial Landscape for Cannabinoids in Neurology: A Registry-Based Systematic Review
This systematic review of cannabinoid clinical trials neurological disorders highlights research focused on Multiple Sclerosis, Fibromyalgia, and Parkinson's Disease. It reveals challenges due to inconsistent protocols and dosing across studies. The…